Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alcon Wins FDA Nods for Unity VCS and Unity CS - Medical Product Outsourcing
OEM News

Alcon Wins FDA Nods for Unity VCS and Unity CS

The new Unity systems debut workflow efficiencies over its current systems for vitreoretinal procedures and cataract surgery.

Alcon has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Unity vitreoretinal cataract system (VCS) and Unity cataract system (CS). They are the first introductions to Alcon’s Unity portfolio.
 
The company said the two new systems debut workflow efficiencies over its current Constellation vision system for vitreoretinal procedures and Centurion vision system with Active Sentry for cataract surgery. There are over 28,000 Centurion and Constellation devices targeted for upgrade to the Unity platform over the next decade.
 
The Unity VCS console is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures.
 
The Unity CS console is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery.
 
Alcon tested Unity VCS and Unity CS during investigational advisory wet lab sessions with over 200 highly experienced surgeons from 30+ countries. The company intends to secure real-world feedback before commercial launch in 2025. CE mark approval is also expected in 2025.
 
The company plans to introduce new Unity products in the coming years.
 
“At Alcon, we have a long legacy of involving our customers throughout the research and development process to deliver bold innovation in ophthalmology, and we would like to thank those who helped us arrive at today’s milestone,” said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. “We are excited to introduce the next generation of equipment solutions and consumables—in cataract and vitreoretinal surgery—and deliver meaningful impact for Eye Care Professionals and patients.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics